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Therapeutic drug monitoringAbstract Antiepileptic drugs are the ﬁrst choice for epilepsy treatment. Monitoring antiepileptic
drugs is important to minimize their adverse side effects by choosing the optimum drug dosage.
An accurate and high throughput supercritical ﬂuid chromatography-tandem mass spectrometry
method has been developed for the simultaneous quantiﬁcation of several antiepileptic drugs in
human plasma. Plasma samples were extracted with ethyl acetate and the upper organic layer
was directly injected into the supercritical ﬂuid chromatography/mass spectrometry (SFC-MS/
MS) system without further nitrogen evaporation and subsequent reconstitution. The analytes were
eluted on a UPC2TM BEH, 2-EP column (100  3 mm, 1.7 lm) at a ﬂow rate of 1.0 mL/min and
multi-reaction monitoring (MRM) was performed for determination of the analytes and internal
standard (IS) in polarity switching mode. Calibration curves were linear over the concentration
ranges of 0.08–40, 0.01–15, 0.01–8 and 0.5–50 lg/mL with lower limit of quantiﬁcations of 0.08,
0.01, 0.01 and 0.50 lg/mL for topiramate, carbamazepine, oxcarbazepine and monohydroxycarba-
mazepine, respectively. This sensitive, accurate, novel method will be very useful for monitoring the
above antiepileptic drugs and for pharmacokinetic studies.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).986321.
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2 L. Wang et al.1. Introduction
Epilepsy is one of the most usual severe neurological disorders (Zhang
et al., 2012). Drugs are the ﬁrst choice for the treatment of epilepsy and
antiepileptic drugs (AEDs) are generally effective in controlling epi-
lepsy; however, side effects of AEDs involving early onset and late
onset events can be observed during therapy (Landmark et al., 2012;
Błaszczyk et al., 2015). In addition, there may be an individual vari-
ability in response to treatment mainly because of pharmacokinetic
variability (Landmark et al., 2012). Among AEDs, the recommended
target plasma concentrations are narrow and, hence, a small change
in plasma concentration may produce toxic or undesirable reactions
following overdosage or underdosage (Kuhn and Knabbe, 2013;
Paglia et al., 2007; Behbahani et al., 2013). To the best of our knowl-
edge, the relationship between a prescribed dosage regimen and its
resultant clinical effects is complex but, the association between the
plasma concentration and the clinical therapeutic effectiveness is pre-
dictable (Hitchings, 2012). Therapeutic drug monitoring (TDM) is
important for maximizing the therapeutic effectiveness and minimizing
any adverse side effects by adjusting the drug dosage (Adaway and
Keevil, 2012).
To achieve this, we have developed a sensitive and robust analytical
method involving a simple sample extraction procedure for monitoring
the plasma concentrations of new AEDs (topiramate, TPM; oxcar-
bazepine, OXC and its major active metabolite monohydroxy carba-
mazepine, MHD) together with a traditional AED (carbamazepine,
CBZ). TPM, OXC and CBZ are available worldwide and in addition,
TPM and OXC were chosen because they are widely used in the pedi-
atric population beyond the approved indications for AEDs (Santulli
et al., 2016). They are associated with serious adverse reactions such
as cognitive and behavioral impairment and language functions
(Jarrar and Buchhalter, 2003; Glauser, 1997). MHD is the main phar-
macologically active metabolite of OXC (a prodrug), found in the
blood after oral dosing (Chollet, 2002). Furthermore, CBZ can also
induce cytochrome P450 enzymes, which can change drug plasma con-
centration of patients (Luke, 2012).
At present, a number of laboratorymethods for the determination of
one ormoreAEDs are used such as high-performance liquid chromatog-
raphy coupled to ultraviolet detection (Serralheiro et al., 2013; Queiroz
et al., 2008) or diode array detection (Saracino et al., 2010; Vosough
et al., 2014), mass spectrometry detection (Shibat et al., 2012; Kim
et al., 2011; Sorensen, 2011; Loureiro et al., 2011; Matar, 2010), follow-
ing extraction procedures which usually include protein precipitation
(Sorensen, 2011), solid-phase extraction (Loureiro et al., 2011), and liq-
uid–liquid extraction (Matar, 2010). Recently, a simple protein precipi-
tation followed by UPLC-MS/MS method has been described to
monitor six AEDs including lacosamide, lamotrigine, levetiracetam,
primidone, topiramate, and zonisamide in serum and plasma (Kuhn
and Knabbe, 2013). However, those above methods have the following
shortcomings: Firstly, a long chromatography separation time may be
required. In addition, a mobile phase containing plenty of commonly
used organic solvents such as acetonitrile, whichmight increase potential
environmental pollution and operating costs. Regarding sample prepa-
ration, the main disadvantage of PP involves lower sensitivity because it
requires dilution of the protein precipitation solution, what’s more, pro-
teins and other interfering substances from biological matrices may
damage the chromatographic column and detector (Adaway and
Keevil, 2012). In addition, SPE involves many steps and is labor inten-
sive, time-consuming and relatively costly (Novakova and Vlckova,
2009). It is also worth mentioning that enzyme multiplied immunoassay
technique (EMIT) has been widely used as a clinical guide for routine
monitoring of AEDs (such as CBZ) (Mulligan and Fleetwood, 1978).
However, EMIT is limited to detection of a single analyte and it is sus-
ceptible to interference from metabolites. Also, the reagents for EMIT
have to be imported and are more expensive.
A supercritical ﬂuid chromatography-electrospray ionization tan-
dem mass spectrometry (SFC-ESI-MS/MS) method employing both
multiple reaction monitoring (MRM) and polarity switching has beenPlease cite this article in press as: Wang, L. et al., Simultaneous determination of
plasma by SFC-ESI-MS/MS with polarity switching: Application to therapeutic
10.1016/j.arabjc.2016.09.016developed for simultaneous monitoring of several AEDs in human
plasma. SFC is a separation technology which conforms to the concept
of ‘‘Green Chemistry” in which the mobile phase is based on supercrit-
ical carbon dioxide CO2 (SFCO2) beyond the critical value in terms of
both temperature and pressure (Beilke et al., 2016). In contrast to
organic solvents, SFCO2 possesses the perfect characteristics of lower
viscosity, lower toxicity, lower cost, better diffusion and so on
(Uchikata et al., 2012a,b). SFC is characterized by providing a higher
diffusivity owing to both a certain percentage of methanol and SFCO2
as the mobile phase, which can achieve wonderful elution and selectiv-
ity of the targets (Geng et al., 2014). In addition, multiple reaction
monitoring (MRM), one of the detection modes of tandem mass spec-
trometry (MS/MS), can provide high selectivity and sensitivity
(Matsubara et al., 2012). SFC-ESI-MS/MS has become a high-
throughput bioanalytical technique which is suitable for the complete
separation of non-polar compounds and even a wider separation range
of analytes by adding a small amount of organic solvent (Uchikata
et al., 2012a,b; Berger and Deye, 1990; Page et al., 1991). Epilepsy
involves the recurrent abnormal discharge of neurons, and effective
concentrations of AEDs need to reach the abnormal discharge sites
of the central nervous system (Luke, 2012). Therefore, AEDs need to
have a low polarity and high lipid solubility. Thus, SFC-ESI-MS/MS
is well suited to the determination of AEDs in human plasma. Further-
more, regarding sample preparation, the upper organic layer of the
extract is directly injected into the SFC-MS/MS system avoiding the
need for nitrogen evaporation to dryness and a reconstitution proce-
dure which is very time-consuming. In this study, we will describe a
completely validated SFC-ESI-MS/MS method for the simultaneous
quantiﬁcation of several AEDs. In addition, monitoring CBZ in
authentic specimens was performed using the SFC-ESI-MS/MS and
EMIT methods. In summary, a novel, rapid, accurate, sensitive
SFC-ESI-MS/MS followed by simple LLE was developed and found
to be suitable for monitoring the above AEDs in human plasma.
2. Experimental
2.1. Chemicals and reagents
Standard samples of TPM, CBZ, OXC, MHD and diazepam
(IS) were obtained from the National Institutes for Food
and Drug Control (Beijing, China). HPLC-grade methanol
and ethyl acetate were purchased from Fisher Scientiﬁc (Pitts-
burgh, USA) and Yuwang Chemical Co., Ltd. (Jinan, China),
respectively. Both CO2 (P99.99%) and N2 (99.999% purity)
were supplied by Shenyang Qianzhen Chemical Gas Co.,
Ltd. (Shenyang, Liaoning, China). Other reagents were of ana-
lytical grade and obtained commercially. Freshly blank human
plasmas were purchased from the Blood Transfusion Center
(Shenyang, China) and stored at 20 C until required.
2.2. Sample collection
Twenty blood samples were taken fromMarch to April in 2015
from the General Hospital of Nanjing Command PLA. The
blood specimens were taken for routine diagnostic purposes.
The collection time was half an hour before the next drug
administration, which was the minimum concentration time.
Blood samples, about 2 mL were collected and then trans-
ferred into heparinized vacuum tubes and centrifuged to
obtain plasma at 13,000 rpm for 10 min at 37 C. A batch of
samples was measured daily at Fuzhou General Hospital of
Nanjing Command PLA with the EMIT method (Luo et al.,
2011), while the others were immediately stored at 20 C
until analyzed by the SFC-ESI-MS/MS method within onetopiramate, carbamazepine, oxcarbazepine and its major metabolite in human
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Nanjing Command PLA. All patients gave their informed
consents.
2.3. Instrument, chromatographic and MS conditions
The ACQUITY UPC2 system with binary solvent manager,
sample manager, column manager and convergence chro-
matography manager was supplied by Waters Corp., Milford,
MA, USA. The separation was performed by injecting a 5 lL
sample onto a UPC2TM BEH, 2-EP column (100 mm  3 mm,
1.7 lm) in less than 2.5 min. The mobile phase consisted of
carbon dioxide and methanol at a ﬂow rate of 1.0 mL/min in
a gradient elution mode, while pure methanol was used as
the compensation solvent at a ﬂow rate of 0.2 mL/min. The
gradient program was as follows: 0–1.6 min, 12% MeOH in
CO2; 1.6–1.75 min, 12–7%; 1.75–2.3 min, 7%; 2.3–2.5 min,
7–12%. The auto sampler was maintained at 4 C while the
column temperature was 50 C. The backpressure of the sys-
tem was maintained at 13.79 MPa. TPM, CBZ, OXC, MHD
and IS were successfully separated under these conditions with
retention times of 1.25, 1.54, 1.50, 1.97 and 1.04 min, respec-
tively. The UPC2 system connected with the mass detector
by a shunt of ﬁxed proportion which was supplied by Waters
Corporation. The monitoring was carried out using a triple-
quadrupole tandem mass spectrometric detector (Waters
Corp., Milford, MA, USA). Detection was achieved by an
electrospray ionization (ESI) interface in multiple reaction
monitoring (MRM) mode with constant polarity switching.
The full scan product ion spectra of analytes and IS are shown
in Fig. 1. The optimal MS conditions were as follows: the
source temperature and desolvation temperature were main-
tained at 150 C, 400 C; the cone and nitrogen ﬂow rates were
set at 10 L/h and 800 L/h, respectively; and the capillary volt-
age was 2.5 kV. The optimized MRM fragmentation transi-
tions and MS parameters for each analyte are listed in
Table 1. All the collected data were processed using MassL-
ynxTM NT 4.1 software with a QuanLynxTM program (Waters
Corp., Milford, MA, USA).
2.4. Preparation of standards, internal standard and quality
control samples
Independently, an appropriate amount of analyte in methanol
was used to obtain stock standard solutions, with a concentra-
tion of 4.0 mg/mL for TPM, CBZ, OXC and MHD, which
were serially diluted using methanol to obtain the working
standard solutions at several concentrations. In addition, stock
standard solutions of IS (1.0 mg/mL) were dissolved in metha-
nol and further diluted to yield 1.0 lg/mL solutions. Further-
more, seven combined spiked solutions were prepared daily by
mixing the working standard solutions of the analytes with
ﬁnal concentrations of 0.8, 1.6, 4.0, 20, 40, 200, 400 lg/mL
for TPM, 0.1, 0.2, 1.0, 5.0, 15, 75, 150 lg/mL for CBZ, 0.1,
0.2, 0.8, 4.0, 8.0, 40, 80 lg/mL for OXC and 5.0, 10, 25, 50,
100, 250, 500 lg/mL for MHD. Calibration standards were
prepared by the addition of 10 lL of appropriate combined
spiked solutions to 100 lL blank plasma, giving ﬁnal desig-
nated plasma concentration ranges of 0.08–40 lg/mL for
TPM, 0.01–15 lg/mL for CBZ, 0.01–8.0 lg/mL for OXC and
0.5–50 lg/mL for MHD. The QC samples were also indepen-Please cite this article in press as: Wang, L. et al., Simultaneous determination of
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of corresponding combined solutions, resulting in ﬁnal plasma
concentrations of 0.16, 2.0 and 32.0 lg/mL for TPM, 0.02, 0.5
and 12 lg/mL for CBZ 0.02, 0.4 and 6.4 lg/mL for OXC, 1.0,
5.0 and 40 lg/mL for MHD corresponding to the three differ-
ent concentration levels. All the stock solutions were stored at
20 C until required for further dilution.
2.5. Sample preparation
Plasma sample preparation was performed by simple LLE
without nitrogen evaporation to dryness and reconstitution.
Aliquots of 100 lL blank plasma sample were transferred to
5 mL Eppendorf tubes, then 10 lL methanol, 10 lL IS (1 lg/
mL) and 150 lL water were added and vortex-mixed for
1 min prior to the addition of the extraction solvent. This
was followed by the addition of 1000 lL ethyl acetate and vor-
texed for another 3 min. After centrifugation at 13,000 rpm for
5 min, the upper organic layer was directly transferred to a vial
and 5 lL was injected into the SFC-MS/MS system.
2.6. Method validation
Validation was performed with respect to the selectivity, lin-
earity and sensitivity, precision and accuracy, matrix effect,
extraction recovery and stability.
The selectivity was evaluated by comparing the chro-
matograms of blank plasma with simulated plasma samples
at LLOQ level. The lower limit of quantiﬁcation (LLOQ)
samples were prepared and validated with a relative error
(RE) within ±20% and RSD lower than 20%. Calibration
curves were prepared as described above and processed by
the internal calibration curve method and weighted by 1/x.
The accuracy and precision were determined based on the
analysis of six replicates of QC samples within the same
day (n= 6; intra-day assay) and over eighteen replicates of
QC samples on different days (n= 18; inter-day assay).
The precision was presented as the relative standard devia-
tion (RSD) while the accuracy was validated with the relative
error (RE). Recovery was assessed by comparing the mean
peak areas of AEDs in plasma samples spiked before LLE
to the peak areas in samples spiked after LLE. The matrix
effect was determined by comparing the mean peak areas
of AEDs in plasma samples spiked after LLE to the peak
areas of analytes added directly to methanol. In order to
evaluate the stability of the analytes in plasma samples, sta-
bility tests were conducted using QC samples of three differ-
ent concentration levels under different conditions: short-
term (kept at room temperature for 8 h), long-term (stored
at 20 C for 30 days), freeze–thaw (three cycles), and
post-preparative (kept in an auto-sampler maintained at
4 C for about 12 h), respectively.
2.7. Practical application and method comparison
In order to demonstrate that the developed SFC-ESI-MS/MS
was applicable for TDM studies, both the SFC-ESI-MS/MS
and EMIT methods were compared by evaluating clinical sam-
ples (Luo et al., 2011). In addition, Bland–Altman plots were
used to assess the bias between these two methods. Compar-
ison studies of clinical specimens were not carried out fortopiramate, carbamazepine, oxcarbazepine and its major metabolite in human
drug monitoring. Arabian Journal of Chemistry (2016), http://dx.doi.org/
Figure 1 The fullscan product ion spectra of (A) CBZ, (B) OXC, (C) MHD, (D) TPM and (E) IS.
Table 1 List of MRM parameters for each analyte and IS.
Analyte Precursor Ion (m/z) Product ion (m/z) Cone voltage (V) Collision energy (V)
TPM 338.2 78.0 57 28
OXC 253.1 180.1 45 31
CBZ 237.2 194.1 40 21
MHD 255.1 193.0 50 20
IS 285.2 193.1 30 28
TPM, topiramate; OXC, oxcarbazepine; MHD, monohydroxy carbamazepine; CBZ, carbamazepine.
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Figure 2 Representative MRM chromatograms of CBZ, OXC, MHD, TPM and IS in human plasma: (A) a blank plasma; (B) a blank
sample spiked with the analytes and IS (at LLOQ level).
Determination of topiramate, carbamazepine, oxcarbazepine and its metabolite in human plasma 5OXC and TPM because they are difﬁcult to obtain and are not
routinely determined at this hospital.3. Results and discussion
3.1. Optimization of chromatographic and mass spectrometry
conditions
Several factors affecting both the chromatographic perfor-
mance and ionization efﬁciency were explored, such as the
compositions of the mobile phase, kinds of modiﬁer, ﬂow-
rate, column temperature, and backpressure.
In the current study, several proportions (95:5, 90:10, 85:15,
v/v) of CO2/methanol under isocratic conditions and several
gradient elution modes were investigated. With the gradient
elution mode described above, sharper peaks, better chromato-
graphic resolutions and suitable retention times for all the ana-
lytes were obtained compared with the other elution modes.
For the composition of mobile phase, both methanol and ace-
tonitrile were investigated, and the results indicated that the
addition of methanol could obtain shaper peaks, better elutionPlease cite this article in press as: Wang, L. et al., Simultaneous determination of
plasma by SFC-ESI-MS/MS with polarity switching: Application to therapeutic
10.1016/j.arabjc.2016.09.016and larger responses of targets than applying acetonitrile. Due
to the fact that supercritical carbon dioxide possessed better
diffusivity compared with organic solvents, the ﬂow rate of
the mobile phase with a good chance of either increasing or
decreasing did not change the column efﬁciency (Li et al.,
2015). Two kinds of columns, ACQUITY UPC2TM HSS C18
SB column (100  3 mm, 1.8 lm) and UPC2TM BEH, 2-EP
column (100  3 mm, 1.7 lm), were investigated to optimize
the chromatographic peak shape and separation of analytes.
The UPC2TM BEH, 2-EP column was shown to be more suit-
able offering better chromatographic performances. Thus, due
to the narrower peak, shorter analysis time and higher
response achieved for all the analytes, 50 C was proved to
be the optimal column temperature out of 40, 45, 50 and
55 C. The compensation solvent could improve the mass
response of the analytes which was in accordance with a previ-
ous study (Liu et al., 2014). Methanol and the different con-
centrations of formic acid (0.1%, 0.2%) in methanol were
investigated, the results indicated that methanol was the best
choice due to the negative ionization switching mode of
TPM, and the addition of formic acid suppressed the
ionization of TPM leading to a lower response.topiramate, carbamazepine, oxcarbazepine and its major metabolite in human
drug monitoring. Arabian Journal of Chemistry (2016), http://dx.doi.org/
Table 3 Extraction recovery and matrix effect at 3 concentrations: QC Low, QC Medium and QC High (n= 6 at Each
Concentration).
Analyte Conc. (lg/mL) Recovery Matrix eﬀect
Mean ± SD (%) RSD (%) Mean ± SD (%) RSD (%)
TPM 0.16 82.24 ± 1.46 1.8 104.3 ± 2.42 2.3
2.00 86.20 ± 0.90 1.0 99.2 ± 8.80 8.9
32.00 82.44 ± 3.47 4.2 102.8 ± 4.15 4.0
CBZ 0.02 79.91 ± 1.42 1.8 90.6 ± 3.08 3.4
0.50 82.66 ± 5.34 6.5 108.3 ± 5.29 4.9
12.00 75.03 ± 4.31 5.7 92.0 ± 5.70 6.2
OXC 0.02 67.49 ± 2.98 4.4 98.8 ± 2.35 2.4
0.40 66.51 ± 5.41 8.1 97.2 ± 3.24 3.3
6.40 68.15 ± 2.63 3.9 97.6 ± 5.29 5.4
MHD 1.00 67.91 ± 3.12 4.6 100.4 ± 2.97 3.0
5.00 65.77 ± 3.69 5.6 97.2 ± 4.93 5.1
40.00 64.97 ± 3.74 5.8 101.8 ± 3.48 3.4
TPM, topiramate; OXC, oxcarbazepine; MHD, monohydroxy carbamazepine; CBZ, carbamazepine.
Table 2 Intra-day and inter-day precision and accuracy at 3 concentrations: QC Low, QC Medium and QC High.
Analyte Conc. (lg/mL) Precision Accuracy
Mean ± SD (lg/mL) Inter-day (RSD %) Intra-day (RSD %) Mean ± SD (%) RSD (%)
TPM 0.16 0.17 ± 0.01 5.4 2.9 103.7 ± 5.45 5.2
2.00 2.07 ± 0.16 8.0 3.8 103.2 ± 8.21 8.0
32.00 30.9 ± 2.30 7.4 2.5 96.7 ± 7.19 11.3
CBZ 0.02 0.18 ± 0.02 7.1 7.2 90.8 ± 6.47 7.4
0.50 0.50 ± 0.04 7.1 5.5 100.6 ± 7.12 7.1
12.00 11.16 ± 0.53 4.7 3.0 93.1 ± 4.41 4.7
OXC 0.02 0.02 ± 0.00 5.0 4.7 83.3 ± 4.20 5.0
0.40 0.38 ± 0.03 8.3 4.8 95.4 ± 7.93 8.3
6.40 5.79 ± 0.25 4.4 4.2 90.2 ± 3.92 4.4
MHD 1.00 1.01 ± 0.06 5.9 5.8 101.2 ± 5.98 5.9
5.00 4.80 ± 0.45 9.6 7.9 95.9 ± 9.15 9.5
40.00 41.3 ± 2.87 6.9 4.8 103.3 ± 7.17 6.9
The values were evaluated by replicate (n= 6) analysis of the QC samples within 1 day (intra-day assay) and replicate (n= 18) analysis of the
QC samples on 3 different days (inter-day assay).
TPM, topiramate; OXC, oxcarbazepine; MHD, monohydroxy carbamazepine; CBZ, carbamazepine.
6 L. Wang et al.The effect of back-pressure (12.41, 13.10, 13.79, 15.17 MPa)
was also studied. However, the back-pressure had little signif-
icant inﬂuence on the chromatographic performance, so a
back-pressure of 13.79 MPa was set for the best instrumental
performance, which was adjusted by the Waters engineers.
In order to validate a sensitive SFC-MS/MS technology, an
electrospray ionization (ESI) interface that operated in polar-
ity switching mode under MRM conditions was examined.
Parameters, such as the capillary voltage, collision energy
and cone voltage, were also adjusted, and a stronger and more
stable response of ion transitions was obtained. TPM was
determined by using the negative ion mode, while the other
AEDs were quantiﬁed in positive ion mode.
3.2. Sample preparation
LLE is a very efﬁcient method because of the lower polarity of
the AEDs. To optimize the LLE procedure so as to obtainPlease cite this article in press as: Wang, L. et al., Simultaneous determination of
plasma by SFC-ESI-MS/MS with polarity switching: Application to therapeutic
10.1016/j.arabjc.2016.09.016higher recoveries, cleaner extracts and negligible matrix effects,
some factors affecting the extraction recovery, such as the type
and volume of the extracting solvent, the centrifugation speed
and time, and vortexed time were taken into account. The
immiscible extraction solvents, ethyl acetate, dichloromethane
and methyl tert-butyl ether, were investigated. The recoveries
for all analytes were within the acceptable range for both ethyl
acetate and methyl tert-butyl ether. Nevertheless, methyl tert-
butyl ether is much more toxic and pungent than ethyl acetate,
so ethyl acetate was selected as the optimum solvent. In addi-
tion, the volume of extraction solvent (in the range of 800–
1200 lL) was studied and 1000 lL was determined to be the
optimum volume in terms of recovery. Because the upper
organic layer was directly injected into the SFC-MS/MS sys-
tem, the drug concentration in the upper organic layer is rela-
tively low. So, we selected 100 lL as the volume of human
plasma so as to maintain a higher sensitivity. Each tube, after
addition of the extraction solvent, was thoroughly vortexedtopiramate, carbamazepine, oxcarbazepine and its major metabolite in human
drug monitoring. Arabian Journal of Chemistry (2016), http://dx.doi.org/
Table 4 Stability of all analytes under different conditions at 3 concentrations: QC Low, QC Medium and QC High (n= 3 at Each
Concentration).
Analyte Conc.
(lg/mL)
Pretreatment for 12 h Room Temperature for 24 h Three freeze-thaw cycles 20 C Frozen storage for
30 days
Found (lg/mL) RSD (%) Found (lg/mL) RSD (%) Found (lg/mL) RSD (%) Found (lg/mL) RSD (%)
TPM 0.16 0.16 ± 0.02 6.7 0.16 ± 0.00 5.8 0.16 ± 0.00 1.9 0.15 ± 0.00 3.8
2.00 2.15 ± 0.06 2.7 2.28 ± 0.07 3.1 2.15 ± 0.13 6.3 2.08 ± 0.13 6.2
32.00 31.8 ± 4.23 13.3 29.3 ± 0.27 1.0 28.8 ± 1.41 4.9 30.7 ± 2.27 7.4
CBZ 0.02 0.02 ± 0.00 2.9 0.02 ± 0.00 11.8 0.02 ± 0.00 7.9 0.02 ± 0.00 3.1
0.50 0.37 ± 0.01 2.8 0.39 ± 0.03 8.6 0.39 ± 0.03 10.6 0.36 ± 0.01 4.9
12.00 6.07 ± 0.80 13.1 6.06 ± 0.20 3.4 5.87 ± 0.24 4.2 5.63 ± 0.15 2.8
OXC 0.02 0.02 ± 0.00 3.3 0.02 ± 0.00 6.2 0.02 ± 0.00 3.3 0.02 ± 0.00 3.1
0.40 0.45 ± 0.01 2.5 0.46 ± 0.01 2.6 0.48 ± 0.04 9.0 0.44 ± 0.01 3.3
6.40 10.9 ± 0.76 7.0 11.03 ± 0.17 1.6 10.8 ± 0.45 4.2 11.0 ± 1.03 9.4
MHD 1.00 1.03 ± 0.03 3.3 1.06 ± 0.01 1.1 0.90 ± 0.07 7.7 0.88 ± 0.04 4.3
5.00 5.27 ± 0.64 12.1 5.11 ± 0.54 10.7 5.21 ± 0.76 14.6 5.22 ± 0.50 9.6
40.00 42.3 ± 3.29 7.8 42.7 ± 1.28 3.0 43.2 ± 0.19 0.4 43.4 ± 3.64 8.4
TPM, topiramate; OXC, oxcarbazepine; MHD, monohydroxy carbamazepine; CBZ, carbamazepine.
Figure 3 Bland-Altman’s graph of CBZ blood concentration
determined by EMIT and SFC-ESI-MS/MS method.
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time, as well as the vortexed time, was investigated in terms
of the recovery. According to the obtained results, 3 min was
selected as the vortexed time with the best efﬁciency. The
obtained results indicated that these parameters were distinctly
ineffective and so, 13,000 rpm and 5 min were selected as the
optimized centrifuge rate and time, respectively. In addition,
the effect of adding water to plasma was studied, and a high
dilution of plasma with 150 lL water was found to eliminate
any matrix effect as far as possible.
3.3. Method validation
Regarding selectivity, the representative chromatograms
obtained from the analysis of blank plasma and the corre-Please cite this article in press as: Wang, L. et al., Simultaneous determination of
plasma by SFC-ESI-MS/MS with polarity switching: Application to therapeutic
10.1016/j.arabjc.2016.09.016sponding spiked plasma at the LLOQ level are shown in
Fig. 2. As can be seen from the chromatograms, none of the
matrix components interfered with the analytes or the IS at
their corresponding retention times, which indicates that the
assay has acceptable selectivity.
Calibration curves were linear over the plasma concentra-
tion ranges of 0.08–40 lg/mL for TPM, 0.01–15 lg/mL for
CBZ, 0.01–8 lg/mL for OXC and 0.5–50 lg/mL for MHD.
The respective linear regression equations of TPM, CBZ,
OXC and MHD were as follows: y= 0.069x+ 0.008
(r2 = 0.9967), y= 32.43x+ 0.2580 (r2 = 0.999), y= 5.214x
+ 0.041 (r2 = 0.9912) and y= 0.049x+ 0.021
(r2 = 0.9947), where y represents the peak area ratio of the
analyte to IS and x is the concentration of the analyte. The
regression coefﬁcients (r2) of all calibration curves were greater
than 0.99. The lowest limit of quantiﬁcation was found to be
0.08, 0.01, 0.01 and 0.5 lg/mL for TPM, CBZ, OXC and
MHD, respectively, which was markedly lower than the target
plasma concentrations reported, indicating that this method
was sensitive enough for all analytes.
The values for the intra- and inter-day precision and
accuracy are presented in Table 2. All the results were within
the acceptable ranges. Further investigations demonstrated
that the novel method was accurate, reliable and
reproducible.
The obtained results for the matrix effect and extraction
recovery of the three levels of QC samples for all the analytes
are listed in Table 3. The extraction recovery and matrix effect
of the IS were 81.0 ± 4.9%, and 90.9 ± 1.2%, respectively.
All the obtained values of the matrix effect were between
85% and 115%, which indicated this method effectively
removed interfering substances from biological matrices.
The stability of all analytes under different conditions is
shown in Table 4. Under all the tested conditions, the results
were less than ±15% deviation from the nominal concentra-
tion, which allowed us to conclude that all analytes were
proved to be stable and the method was reliable.topiramate, carbamazepine, oxcarbazepine and its major metabolite in human
drug monitoring. Arabian Journal of Chemistry (2016), http://dx.doi.org/
0Figure 4 Representative chromatograms of real samples from two different patients with carbamazepine: (A) 8.49 lg/mL; (B) 4.25 lg/mL.
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Data distribution obtained by both SFC-ESI-MS/MS and
EMIT methods is shown in the Bland-Altman graph, where
the average difference was between 0.97 and 3.58, and the
standard deviation was 1.3 (Fig. 3). The CBZ blood concen-
trations determined by EMIT were higher than those obtained
by SFC-ESI-MS/MS. Representative chromatograms of two
different authentic samples are shown in Fig. 4. We have
demonstrated that the SFC-ESI-MS/MS approach was appli-
cable for the determination of authentic samples with good
speciﬁcity, precision and accuracy.
EMIT and SFC-ESI-MS/MS methods were used to deter-
mine CBZ blood concentrations. The Bland-Altman graph of
the CBZ blood concentrations exhibited a negative bias, which
is consistent with the literature references (Liu et al., 1993;
Shibat et al., 2012). The greater degree of EMIT was due to
cross-reaction of the EMIT reagent with other interfering sub-
stances such as structural analogs, its major metabolite and the
matrix itself (Burianova and Borecka, 2015).
3.5. Limitations
The developed SFC-ESI-MS/MS approach with many advan-
tages will be signiﬁcant for monitoring the above AEDs. How-
ever, this method has the following shortcomings: Firstly, the
accuracy of quantitation may be compromised by the lack of
dedicated isotopically labeled internal standards. Therefore,
the test is not appropriate for patients who have taken or been
administered diazepam, within 7 days prior to the sample col-
lection or during the study. In addition, this study has not been
evaluated with authentic samples for the drugs included in the
panel, other than CBZ.
4. Conclusions
A rapid, high-throughput SFC-ESI-MS/MS approach involving LLE
was developed and then validated for simultaneous monitoring of
the above AEDs in human plasma. This approach has been success-
fully used to analyze authentic samples from patients treated with
CBZ. This sensitive, accurate, novel SFC-ESI-MS/MS method involv-
ing LLE will be very useful for monitoring all the above AEDs and
carrying out pharmacokinetic studies.
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